Disease · MONDO_0001673
Comparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 26
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Crofelemer 125Mg BID vs Placebo BID: Primary Efficacy Outcome is Count of Participants With Two or Less Watery Bowel Movements Per Week During at Least Two Weeks of the Treatment Phase of the Optimal Dose of Crofelemer Compared to Placebo | 24 of 136 | 11 of 138 | 274 | NCT00547898 | Trial comparisons |
| Rifamycin SV MMX vs Placebo: Clinical Cure | 162 of 199 | 35 of 65 | 264 | NCT01142089 | Trial comparisons |
| Rifamycin SV MMX vs Placebo: deaths from any cause | 0 of 199 | 0 of 65 | 264 | NCT01142089 | Trial comparisons |
| Rifamycin SV MMX vs Placebo: serious adverse events | 2 of 199 | 1 of 65 | 264 | NCT01142089 | Trial comparisons |
| Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: Objective Response Rate | 65 of 115 | 66 of 115 | 230 | NCT01718873 | Trial comparisons |
| Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: deaths from any cause | 2 of 115 | 2 of 115 | 230 | NCT01718873 | Trial comparisons |
| Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: Disease Control Rate | 107 of 115 | 103 of 115 | 230 | NCT01718873 | Trial comparisons |
| Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: serious adverse events | 65 of 115 | 75 of 115 | 230 | NCT01718873 | Trial comparisons |
| Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: Toxic Effects | 108 of 114 | 113 of 115 | 229 | NCT01718873 | Trial comparisons |
| Carbowhite vs Carbowhite Placebo: Compliance Rate | 0 of 120 | 0 of 24 | 144 | NCT03633344 | Trial comparisons |
| Carbowhite vs Carbowhite Placebo: Reduction in Frequency of Defecation to 3 Times Per Day | 118 of 120 | 24 of 24 | 144 | NCT03633344 | Trial comparisons |
| Carbowhite vs Carbowhite Placebo: deaths from any cause | 0 of 120 | 0 of 24 | 144 | NCT03633344 | Trial comparisons |
| Carbowhite vs Carbowhite Placebo: serious adverse events | 0 of 120 | 0 of 24 | 144 | NCT03633344 | Trial comparisons |
| iOWH032 vs Placebo: Number of Participants With Treatment-emergent Serious Adverse Events | 0 of 23 | 1 of 24 | 47 | NCT04150250 | Trial comparisons |
| iOWH032 vs Placebo: deaths from any cause | 0 of 23 | 0 of 24 | 47 | NCT04150250 | Trial comparisons |
| iOWH032 vs Placebo: serious adverse events | 0 of 23 | 1 of 24 | 47 | NCT04150250 | Trial comparisons |
| Low Dose ECC Regimen vs High Dose ECC Regimen: deaths from any cause | 0 of 13 | 0 of 13 | 26 | NCT04046328 | Trial comparisons |
| Low Dose ECC Regimen vs High Dose ECC Regimen: serious adverse events | 0 of 13 | 0 of 13 | 26 | NCT04046328 | Trial comparisons |
| Crofelemer vs Placebo: deaths from any cause | 0 of 9 | 0 of 8 | 17 | NCT04486326 | Trial comparisons |
| Crofelemer vs Placebo: serious adverse events | 0 of 9 | 0 of 8 | 17 | NCT04486326 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001673/comparisons